Lobe Sciences Provides Corporate Update to Investors and Stakeholders
Retrieved on:
Monday, September 13, 2021
PTSD, SAB, Heroic theory of invention and scientific development, FDA, Washington State, Concussion, Mental health, Intellectual property, University, CEO, Forward-looking statement, Post-traumatic stress disorder, Failure, Coronavirus Scientific Advisory Board (Turkey), Washington, THIS, Conference, NAC, NFL, Perception, Company, OTC Markets Group, Calendar, CRO, PCT, THE, IND, Device, Industry, Association, CSE, Therapy, World, Growth, Psilocybin, COVID-19, News, World Boxing Association, Composition, Organization, CGMP, Acquisition, Time, Research, CSO, Principal investigator, Method, Management, Pharmaceutical industry, Medical device, Nightclub, Animal, Fine chemical
Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:
Key Points:
- Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:
Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts,
We are pleased to say that 2021 has been a busy and transformative year for the Company. - During 2021, we have made significant progress on several fronts, and completed our transition to an integrated pharmaceutical development company.
- We believe that psychedelic based therapeutics will bring a new era of treatment for many illnesses where current therapies are insufficient or unavailable.
- Lobe Sciences is a life sciences company focused on psychedelic medicines.